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Abstract
Background: The aim of this study was to detect the expression of hypoxia-inducible factor (HIF)-1α and HIF-2α in
papillary thyroid carcinoma (PTC) compared with normal thyroid tissues.
Methods: The mRNA levels and protein levels of HIF-1α and HIF-2α were detected by real-time PCR and Western blot
separately in 30 pairs of PTCs and normal thyroid cases. The protein levels were also detected by immunohistochemistry
(IHC) using 92 samples of PTC group and 46 normal samples as control group for analyzing the biological and clinical
significance of the expression of HIF-1α/HIF-2α.
Results: Real-time PCR results showed the mRNA level of HIF-1α and HIF-2α were significantly higher in PTC than
normal group (P < 0.001). Also, significantly higher positive rates (73 %/65 %) of HIF-1α and HIF-2α were observed in
PTC compared with the control group (27 %/35 %) by IHC (P < 0.01); the consistent results were gotten with Western
blot. Although we did not find a significant correlation between the expression of HIF-1α and HIF-2α with gender, age,
calcification, or Hashimoto’s disease in the present study (P > 0.05), both of their expressions were correlated to lymph
node metastasis (P < 0.05), capsular invasion (P < 0.05), and TNM stage (P < 0.05).
Conclusions: Overexpression of HIF-1α and HIF-2α are associated with the carcinogenesis of PTC, served as potential
biomarkers of PTC.
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Background
As one of the most common endocrine tumor, thyroid
cancer has become the fifth highest incidence of malig-
nant tumor among American women [1]. The incidence
of thyroid cancer, especially papillary thyroid carcinoma
(PTC), was increased constantly over the recent years at
a remarkable rate, averaging almost 4 % per year [2].
About 60,220 new cases were reported in 2013 [3] which
have attracted much attention.
The PTC shows some special biological behaviors,
such as it is easily accompanied with calcification or
cystic in the development of tumor although the volume
is small, and it is easily accompanied with lymph node
metastasis (LNM) [4]. As we know, tumor growth
requires the presence of a local vascular network that
supplies both oxygen and nutrients to tumor cells. And
most tumor cells have adapted to and can grow in a
hypoxic condition. Such hypoxic zones have been postu-
lated to increase patient treatment resistance and favor
tumor progression [5, 6].
Hypoxia-inducible factor (HIF), known as a hete-
rodimer transcription factor consisting of an oxygen-
sensitive alpha subunit (HIF-α) and a constitutive beta
subunit (HIF-β) [7], is closely associated with the forma-
tion of hypoxic microenvironment [8]. Under hypoxia,
HIF-α subunits are stabilized and translocated to the
nucleus where they heterodimerize with arylhydrocarbon
receptor nuclear translocator (ARNT) and bind to
hypoxia response elements (HREs) located within
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regulatory elements of HIF target genes. There are three
types of HIF-α subunits, HIF-1α, HIF-2α, and HIF-3α,
and at present, the HIF-1α and HIF-2α gained more
attention [9–12]. Although it has been reported that HIF
is associated with tumorigenesis [13] or radiosensitivity
[14], reports on how HIF-1α and HIF-2α affect the
oncogenesis showed inconsistent results [15, 16]. And
overexpression of HIF-1α and HIF-2α correlated with
different kinds of cancers, respectively [17, 18].
Thus, the aim of this study was to investigate the
expression of HIF-1α and HIF-2α in papillary thyroid
carcinoma and its roles in the development of PTC.
Methods
Patients and specimens
All the materials were obtained with agreement of
patients and signed the informed consent. The usage of
human materials for analysis was approved by the local
ethical committee. All PTCs were staged according to
the International Union Against Cancer (UICC) 2009
guidelines [19]. Ninety-two samples of PTC group (age
range from 23 to 72 years, 58 male and 34 female) and
control group (46 cases total, age range from 21 to
76 years, 19 male and 27 female) were collected from pa-
tients who underwent surgical resection at the Department
of Tai Zhou Central Hospital between January to October
in 2013, and the control samples were relatively normal
tissues from the nodular goiters. All cases were confirmed
by pathologists and divided into nine groups by age, sex,
tumor size, etc. All tissue samples were obtained from the
patients prior to any medical treatment.
RNA extraction and first-strand cDNA synthesis
Of each sample, 50- to 100-mg tissues from 30 fresh fro-
zen tumors and normal tissues, respectively, were used
to isolate total RNA with TRIzol reagent (Invitrogen,
Camarillo, CA, USA). All the processes of RNA extrac-
tion were done on ice, and all the workers wear masks
and gloves to prevent the degradation of RNA. The
amount and quality of the extracted RNA were deter-
mined by the Nano Drop Spectrophotometer (Thermo
Scientific, Wilmington, DE, USA). The cDNA synthesis
was performed under the condition of 37 °C for 60 min in
a volume of 20 μL containing 2 μL RNA, 2 μL 10 × RT
mix, 2 μL dNTP, 2 μL Oligo-dT15, 1 μL Quant Reverse
Transcriptase, and 11 μL RNase-free ddH2O in reaction
buffer.
Real-time polymerase chain reaction
The primer sequences used herein were HIF-1α forward
5′-ACTTCTGGATGCTGGTGATTTG-3′, reverse 5′-
GCTTCGCTGTGTGTTTTGTTCT-3′; HIF-2α forward
5′-TCATGCGACTGGCAATCAGC-3′, reverse 5′-GTC
ACCACGGCAATGAAACC-3′; and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) forward 5′-CAAA
GCTGGTGTGGGAGG-3′, reverse 5′-CTCCTGGAAG
ATGGTGATGG-3′. SYBR Green mix, cDNA template,
0.3 μL forward primer, 0.3 μL reverse primer, and ddH2O
were added into the reaction system (20 μL total volume).
All samples were amplified using the following standard
PCR system: 95 °C pre-degeneration for 2 min, 95 °C
degeneration for 15 s, 60 °C annealing for 30 s, and 68 °C
extension for 60 s within 40 circulations. After reactions
were completed, baseline and threshold were adjusted in
the ABI 7500 software system (Applied Biosystem, USA)
where the cycle threshold (CT) value of each reaction hole
was read. This reaction has been repeated for three times.
Data were analyzed according to the comparative CT
value method and were normalized according to the
GAPDH expression in each sample.
Immunohistochemical analysis
One representative paraffin-embedded block from each
case was selected and sectioned serially at 4 μm. Slides
were baked at 68 °C for 2 h and soaked in xylene; anti-
gen retrieval was performed by boiling the slides with
citrate puffer (pH = 6) at 95 °C, then blocked by normal
goat serum. The samples were incubated with an anti-
body against HIF-1α (1:100; rabbit monoclonal, clone;
ab51608; Abcam; USA) and HIF-2α (1:250; rabbit mono-
clonal, clone; ab20654; Abcam; USA) in an automatic
immunostainer and kept at 4 °C overnight. Then, the
immunostainer was put in 37 °C for 60 min before a sec-
ondary antibody (ZB-2010; Zhongshan Golden Bridge
Biotechnology, China) was added, and then treated with
DAB (diaminobenzidine) for 2 min. The sections were
investigated using a multiheaded microscope by two
investigators who were blinded to the patients’ clinical
information.
Stromal staining of HIF expression was graded semi-
quantitatively as follows: I, no stromal staining; II, little,
staining in <10 % of stroma; III, moderate, staining
in ≥10 and ≤50 %; IV, strong, staining in >50 % of stroma.
For statistical analysis, a final staining score of I or II was
combined into the low expression group, and a final
staining score of III or IV was combined in the high
expression group.
Protein preparation and Western blotting analysis
Of each sample, 50- to 100-mg tissues from 30 fresh fro-
zen tumors and normal tissues were minced on the ice
and sonicated in protein lysis buffer. Then, the protein
was collected by centrifuging at 10,000–14,000 rpm for
5 min; total of 30–50 mg of protein from each case was
loaded on 10 % SDS polyacrylamide gels and separated
by SDS-PAGE, then transferred to PVDF membranes.
After blocking with 5 % non-fat milk in TBS-T for 1.5 h,
the membranes were treated with the primary antibodies
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of HIF-1α (1:1000; Abcam; USA), HIF-2α (1:1000;
Abcam; USA), and β-actin (1: 3000, Abcam; USA) for
1.5 h at 37 °C, and then kept the membrane at 4 °C
overnight. After that, the membranes were incubated
with the secondary antibody at an appropriate concen-
tration for 1.5 h. The bands were visualized using an
enhanced chemiluminescence detection system.
Statistical analysis
Statistical analysis was performed by SPSS 17.0 (SPSS
Inc., Chicago, IL, USA) statistical software. Continuous
variables were expressed as a mean with standard devi-
ation and analyzed using Student’s t test (two-tailed).
Comparison of the clinicopathological parameters with
HIF-1α and HIF-2α expression between the tumor and
normal tissues was conducted by the two-tailed chi-
square test. The correlation between the expression of
HIF-1α and HIF-2α was detected by Spearman rank.
P value <0.05 was considered to be statistically significant.
Results
Immunohistochemistry expression of HIF-1α and HIF-2α
in PTC
The protein levels of HIF-1α and HIF-2α were first mea-
sured by immunohistochemistry (IHC) on paraffin slides
of 92 samples of PTC and paired 46 relatively normal
tissues. The positive staining of HIF-1α was located in
the cytoplasm and the nuclei, but the unequivocal
HIF-2α staining was observed mainly in the cytoplasm
(Fig. 1). Overexpression of HIF-1α was found in 67 (73 %)
of tumor tissues and in 11 (27 %) of the normal group. In
consistence, high expression of HIF-2α was also found in
60 (65 %) of tumor tissues, compared with 15 (35 %) of
the other group. The differences in HIF-1α and HIF-2α
protein expression between PTCs and normal tissues were
statistically significant (P < 0.01) (Table 1).
Western blot expression of HIF-1α and HIF-2α in PTC
To explore the expression of HIF-1α and HIF-2α in
PTC, Western blot was also applied to detect the protein
levels of them in four paired PTC specimens. As shown
in Fig. 2, the protein level of HIF-1α in PTC tissues was
significantly higher than that in control tissues, the same
as HIF-2α.
Correlations of HIF-1α and HIF-2α protein expression with
clinicopathological parameters
Significant correlations of HIF-1α and HIF-2α ex-
pression with clinicopathological parameters are listed in
Fig. 1 Hypoxia-inducible factor in a papillary thyroid carcinoma. a Representative images of HIF-1α in PTC. b Representative images of HIF-1α in
normal. c Representative images of HIF-2α in PTC. d Representative images of HIF-2α in normal; ×400
Table 1 Immunohistochemistry results
Team HIF-1α χ2 P value HIF-2α χ2 P value
High Low High Low
Tumor 67 25 60 32
Normal 11 35 29.86 <0.01 15 31 13.14 <0.01
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Table 2. Regarding the clinical data, no gender-specific
distribution was found both in HIF-1α (P = 0.223) and
HIF-2α (P = 0.725).There were also no specific dif-
ferences in HIF-1α and HIF-2α protein expression be-
tween older (>45) and younger (≤45) patients (P = 0.882,
P = 0.675). Both calcification and Hashimoto’s disease of
the PTC showed no significant correlation with HIF-1α
(P = 0.230; P = 0.410) and HIF-2α expression (P = 0.463;
P = 0.256).
Correlation of expression of HIF-1α in PTC tissues
was not seen between the larger (≥1) and smaller (<1)
tumor size (P = 0.782); however, significant differences
were observed in HIF-2α expression (P = 0.043). Addition-
ally, chi-square test showed a significant association be-
tween the presence of lymph node metastasis with HIF-1α
(P = 0.006) and HIF-2α expression (P = 0.037).There was
also a statistical significance between capsular invasion
with the expression of HIF-1α (P = 0.012) and HIF-2α
(P = 0.004). Generally, patients with unequivocal HIF-1α
and HIF-2α staining exhibited a higher incidence of cap-
sular invasion than patients with negative or equivocal
HIF-1α and HIF-2α expression. Patients with high HIF-1α
staining exhibited a higher TNM stage than patients with
low HIF-1α expression (P = 0.021), the same as HIF-2α
(P = 0.009).
mRNA expression of HIF-1α and HIF-2α in PTCs
The mRNA levels of HIF-1α and HIF-2α were showed
in Fig. 3. The relative expression of HIF-1α mRNA in
PTC was 1.9948 ± 0.3952, and significant differences
were observed (t = 13.784, P < 0.001); the HIF-2α mRNA
was 1.5691 ± 0.3889, which is apparently higher than the
normal. (t = 5.237, P < 0.001). According to these results,
it is clearly showed that both mRNA and protein expres-
sion levels of HIF-1α and HIF-2α were higher in PTCs
than the paired normal tissues.
The correlation of HIF-1α and HIF-2α expression
The correlation of HIF-1α and HIF-2α protein expres-
sion was assessed by Spearman rank test. As shown in
Table 3. Forty-eight (52 %) PTCs displayed high expres-
sion, and 13 (14 %) showed low expression for both
HIF-1α and HIF-2α. The correlation between them was
statistically significant (rs = 0.221, P = 0.034).
Discussion
Hypoxia is a common condition found in a range of
solid tumors and has been increasingly recognized to
play a key role in different stages of tumor progression
[20]. The adaptation of tumor to hypoxia is predomin-
antly regulated by HIF-1α and HIF-2α; while highly
homologous, HIF-1α and HIF-2α have unique tissue dis-
tributions and play critical but non-overlapping roles in
tumor progression [21]. HIF-1α has been implicated as a
tumor promoter, while it has been suggested that HIF-2α
Fig. 2 The expression of HIF-1α and HIF-2α protein in PTC tissue
and the paired normal tissue was confirmed by Western blotting.
Beta-actin was applied as a control. N normal, T tumor
Table 2 Correlation of clinicopathological/morphological
parameters and HIF-1α/HIF-2α expression
Clinical
Characteristics
PTC HIF-1α HIF-2α
Total (+) (+)
n (%) n (%) n (%)
92 (100 %) 67 (73 %) P value 60 (65 %) P value
Gender
Female 64 (70) 49 (67) 41 (64)
Male 28 (30) 18 (64) 0.223 19 (68) 0.725
Age (year)
≥ 45 49 (53) 36 (74) 31 (63)
< 45 43 (47) 31 (72) 0.882 29 (67) 0.675
Tumor size (cm)
≥ 1 42 (40) 30 (71) 32 (76)
< 1 50 (60) 37 (74) 0.782 28 (56) 0.043*
Lymph node
metastasis
Yes 51 (55) 43 (84) 38 (75)
No 41 (45) 24 (59) 0.006* 22 (54) 0.037*
Calcification
Yes 35 (38) 23 (66) 21 (60)
No 57 (62) 44 (77) 0.230 39 (68) 0.410
Capsular invasion
Yes 56 (61) 46 (82) 43 (77)
No 36 (39) 21 (58) 0.012* 17 (47) 0.004*
TNM stage
I–II 52 (59) 33 (64) 28 (51)
III–IV 40 (41) 34 (85) 0.021* 32 (77) 0.009*
Hashimoto’s
disease
Yes 62 (67) 47 (76) 38 (61)
No 30 (33) 20 (67) 0.463 22 (73) 0.256
HIF hypoxia-inducible factor
*P < 0.05
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act as a tumor suppressor gene [22]. To date, studies have
observed that HIF-1α and HIF-2α are overexpressed in
several human tumors, such as ovarian, esophageal, head
and neck [26], breast, prostate, bladder, and oral epithe-
lium [23–26]. Moreover, there have been several studies
which respectively showed that HIF-1α [27] and HIF-2α
[28] are both upregulated in thyroid carcinoma compared
with normal thyroid or benign lesion. However, no studies
have examined the expression of HIF-1α and HIF-2α
under the same condition and systematically assessed the
correlation of their expression with clinicopathological
features in PTC simultaneously. In the present study, we
observed that an overexpression of HIF-1α and HIF-2α is
present in a majority of PTC compared to normal tissues.
As the first HIF family member [29, 30], HIF-1 is an
important transcription factor in the development of
several tumors. HIF-2α, a gene with high construction
gene similarity with HIF-1α, contains 48 % the same
basic amino acid sequences, basic helix-loop-helix
(bHLH) area with 83 % similarity, and per-amt-sim (PAS)
area with 70 % similarity. Recent studies of HIF-2α failed
to show consistent results on how HIF-1α and HIF-2α
affect the PTC development [31–33]. Our results demon-
strated that the positive rate of HIF-1α and HIF-2α in
PTCs was 67 (73 %) and 60 (65 %) higher than those in
normal thyroid, respectively (P < 0.01), which indicated
overexpression of HIF-1α and HIF-2α in PTCs, which was
confirmed by real-time PCR and Western blot.
The correlation of HIF-1α protein expression with sev-
eral clinicopathological parameters was also assessed.
We found that HIF-1α and HIF-2α protein expression
was not associated with gender, age, tumor size, calcifi-
cation, and Hashimoto’s disease. However, there was a
significant correlation of HIF-1α protein expression rela-
tive to TNM stage (P = 0.021) and LNM (P = 0.006). The
overexpression of HIF-1α was associated with capsular
invasion and high TNM stage and LNM. These results
suggested that HIF-1α may play an important role in
invasion, metastasis, and progression of PTC. The same
with HIF-1α, HIF-2α protein expression was not associ-
ated with gender, age, calcification, and Hashimoto’s dis-
ease and correlated to TNM stage (P = 0.009) and LNM
(P = 0.037). However, there is a significant association
between tumor size and HIF-2α (P = 0.035). To date,
there is no report about tumor size like ours. It is neces-
sary to further explore the mechanisms. So far, our data
confirm the role of HIF-2α in the tumor progression of
PTC.
Interestingly, this study demonstrated a significantly
positive correlation between HIF-1α and HIF-2α protein
expression in PTCs for the first time. HIF-1α expression is
positively associated with HIF-2α expression (P = 0.034).To
date, there was no study could explain this positive correl-
ation in PTCs. It is necessary for us to explore mechanisms
underlying this correlation.
Besides HIF-1α and HIF-2α, the other hypoxia family
members, HIF-3α for instance, are also involved in cellular
responses to hypoxia. HIF-3α has an ability to compete
with HIF-1α and HIF-2α to bind with HIF-1β subunits,
reducing the levels of HIF-1 and HIF-2, thereby inhibiting
the up-regulation of target gene expression induced by
HIF-1 and HIF-2 [34]. So, it may also be involved in the
development and progression of PTC, and we need to
Fig 3 PCR analysis of cDNA reverse-transcribed from mRNA of HIF-1α and HIF-2α in PTC tissues and the normal tissue. GAPDH was used as
a control
Table 3 Correlation of HIF-1α and HIF-2α protein expression
HIF-2α rs P
HIF-1α High Low
High 48 19 0.221 0.034
Low 12 13
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conduct more extensive studies to understand the roles
they play in this progress.
This study compares the expression of HIF-1α and
HIF-2α in PTCs and normal tissues separately at the
level of gene and protein. To our knowledge, it is the
first time to demonstrate the significantly positive cor-
relation between HIF-1α and HIF-2α protein expression
in PTCs. However, in the present study, it mainly
focuses on tissues. Much more extensive studies about
mechanisms at the cellular and molecular levels would
be needed in the coming future.
Conclusions
To our knowledge, this is the first study that demon-
strates the positive correlation between HIF-1α and
HIF-2α in PTCs. High expression of HIF-1α and HIF-2α
was associated with high TNM stage and LNM. Conse-
quently, our results provide a possible basis for predic-
tion of LNM and progression in PTC and may provide
new therapeutic options targeting hypoxia-associated
and hypoxia-regulated proteins. However, the underlying
mechanisms still need further exploration, and future
studies in larger sets of patients will be necessary to
determine the utility of these molecules as biomarkers of
tumor diagnosis and prognosis in PTC.
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